Practical use of apomorphine infusion in Parkinson's disease: lessons from the TOLEDO study and clinical experience

被引:5
|
作者
Henriksen, Tove [1 ]
Katzenschlager, Regina [2 ,3 ]
Bhidayasiri, Roongroj [4 ,5 ,6 ]
Staines, Harry [7 ]
Lockhart, Donna [8 ]
Lees, Andrew [9 ,10 ]
机构
[1] Univ Hosp Bispebjerg, Movement Disorder Clin, Dept Neurol, DK-2400 Copenhagen, Denmark
[2] Klin Donaustadt, Dept Neurol, Vienna, Austria
[3] Klin Donaustadt, Karl Landsteiner Inst Neuroimmunol & Neurodegenera, Vienna, Austria
[4] Chulalongkorn Univ, Fac Med, Chulalongkorn Ctr Excellence Parkinsons Dis & Rela, Dept Med, Bangkok, Thailand
[5] King Chulalongkorn Mem Hosp, Thai Red Cross Soc, Bangkok, Thailand
[6] Royal Soc Thailand, Acad Sci, Bangkok, Thailand
[7] Sigma Stat Serv, Balmullo, England
[8] Britannia Pharmaceut Ltd, Reading, Berks, England
[9] UCL, Queen Sq Inst Neurol, Queen Sq, London, England
[10] Natl Hosp, Queen Sq, London, England
关键词
Parkinson's disease; Apomorphine infusion; Clinical practice; MOTOR FLUCTUATIONS; EFFICACY; THERAPY;
D O I
10.1007/s00702-023-02686-7
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Subcutaneous apomorphine infusion is a device-aided therapy for Parkinson's disease that can be considered when motor fluctuations become persistent and are no longer adequately controlled by oral/transdermal medication. Apomorphine infusion is less invasive than enteral levodopa, deep brain stimulation or focused ultrasound, and is often indicated even when neurosurgical approaches are contraindicated. This article aims to provide practical guidance for doctors and nurses initiating and treating patients with apomorphine infusion, and is based on both trial data and clinical experience from movement disorders specialists. A post hoc analysis of data from the TOLEDO randomized clinical trial of apomorphine infusion was conducted along with an analysis of 'real world' experience from 13 movement disorders specialists using a questionnaire that focused on starting patients on apomorphine infusion. Practical guidelines for starting treatment with apomorphine infusion are provided taking into consideration the regional disparities in healthcare. Apomorphine infusion is straightforward to administer but to be successful it requires concordance from the patient and family, and clinical support from an experienced team of doctors and nurses, particularly in the early months of treatment.
引用
收藏
页码:1475 / 1484
页数:10
相关论文
共 50 条
  • [31] APOmorphine infusion and aMYLoid deposition in Parkinson's disease (APOMYL): preliminary clinical and amyloid imaging data
    van Wamelen, Daniel
    Politis, Marios
    Aarsland, Dag
    Odin, Per
    van Laar, Teus
    Henriksen, Tove
    Corcoran, Ben
    Vivian, Gillian
    Parry, Miriam
    Mulholland, Nicola
    Chaudhuri, K. Ray
    NEUROLOGY, 2019, 92 (15)
  • [32] APOmorphine infusion and aMYLoid deposition in Parkinson's disease (APOMYL): preliminary clinical and amyloid imaging data
    van Wamelen, D.
    Politis, M.
    Aarsland, D.
    Odin, P.
    van Laar, T.
    Henriksen, T.
    Corcoran, B.
    Vivian, G.
    Wilson, H.
    Parry, M.
    Sauerbier, A.
    Mulholland, N.
    Chaudhuri, K.
    MOVEMENT DISORDERS, 2019, 34
  • [33] Continuous subcutaneous apomorphine infusion in advanced Parkinson's disease: 10-year experience with 230 patients
    Sesar, Angel
    Fernandez-Pajarin, Gustavo
    Ares, Begona
    Teresa Rivas, Maria
    Castro, Alfonso
    JOURNAL OF NEUROLOGY, 2017, 264 (05) : 946 - 954
  • [34] Continuous subcutaneous apomorphine infusion in advanced Parkinson’s disease: 10-year experience with 230 patients
    Ángel Sesar
    Gustavo Fernández-Pajarín
    Begoña Ares
    María Teresa Rivas
    Alfonso Castro
    Journal of Neurology, 2017, 264 : 946 - 954
  • [35] Ambulatory treatment with continuous subcutaneous apomorphine infusion in advanced Parkinson's disease. Experience with 34 cases
    Sesar, A.
    Ares, B.
    Rivas, M. T.
    Castro, A.
    MOVEMENT DISORDERS, 2008, 23 (01) : S313 - S314
  • [36] Long-term safety and efficacy of apomorphine infusion in Parkinson's disease patients with persistent motor fluctuations: Results of the open-label phase of the TOLEDO study
    Katzenschlager, Regina
    Poewe, Werner
    Rascol, Olivier
    Trenkwalder, Claudia
    Deuschl, Guenther
    Chaudhuri, K. Ray
    Henriksen, Tove
    van Laar, Teus
    Lockhart, Donna
    Staines, Harry
    Lees, Andrew
    PARKINSONISM & RELATED DISORDERS, 2021, 83 : 79 - 85
  • [37] Apomorphine infusion does not impair cognitive action control in Parkinson's disease
    Duprez, J.
    Houvenaghel, J. F.
    Drapier, S.
    Drapier, D.
    Verin, M.
    Sauleau, P.
    MOVEMENT DISORDERS, 2017, 32
  • [38] Continuous Subcutaneous Apomorphine Infusion in Advanced Parkinson's Disease: A Systematic Review
    Gaire, Suman
    Kafle, Sunam
    Bastakoti, Sanjiv
    Paudel, Anuj
    Karki, Kumar
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2021, 13 (09)
  • [39] Duodenale levodopa and apomorphine infusion for motor complications in advanced Parkinson's disease
    Antonini, Angelo
    Jost, Wolfgang H.
    FORTSCHRITTE DER NEUROLOGIE PSYCHIATRIE, 2018, 86 : S5 - S9
  • [40] Continuous Subcutaneous Infusion Delivery of Apomorphine in Parkinson's Disease: A Systematic Review
    Kukkle, Prashanth Lingappa
    Garg, Divyani
    Merello, Marcello
    MOVEMENT DISORDERS CLINICAL PRACTICE, 2023, 10 (09): : 1253 - 1267